Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Coffwell-D is a combination oral syrup developed and marketed by Wellmed Pharma for the symptomatic relief of cough, nasal congestion, and allergic symptoms associated with the common cold and upper respiratory tract conditions. It is a multi-ingredient formulation containing dextromethorphan hydrobromide, phenylephrine hydrochloride, and chlorpheniramine maleate. Dextromethorphan acts as an antitussive by suppressing the cough reflex in the brain. Phenylephrine is a sympathomimetic decongestant that targets alpha-adrenergic receptors to reduce swelling in the nasal passages. Chlorpheniramine is a first-generation antihistamine that blocks H1 receptors to alleviate sneezing, itching, and watery eyes. This product is positioned as a branded generic in the Indian pharmaceutical market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Coffwell-D.